Trial · NCT02563067
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation | QAW039 150 mg | 0.73 | 95% Confidence Interval 0.57 to 0.94 | Events/year | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation | QAW039 450 mg | 0.76 | 95% Confidence Interval 0.59 to 0.99 | Events/year | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation | Placebo | 1.06 | 95% Confidence Interval 0.84 to 1.33 | Events/year | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation | QAW039 150 mg | 0.73 | Standard Error 0.061 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation | QAW039 450 mg | 0.71 | Standard Error 0.062 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation | Placebo | 0.58 | Standard Error 0.062 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5 (ACQ-5) Score in High Eosinophils Subpopulation | QAW039 150 mg | -0.92 | Standard Error 0.067 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5 (ACQ-5) Score in High Eosinophils Subpopulation | QAW039 450 mg | -0.84 | Standard Error 0.068 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5 (ACQ-5) Score in High Eosinophils Subpopulation | Placebo | -0.75 | Standard Error 0.069 | units on a scale | |
| Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation | QAW039 150 mg | 0.192 | Standard Error 0.0306 | Liter | |
| Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation | QAW039 450 mg | 0.162 | Standard Error 0.0311 | Liter | |
| Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation | Placebo | 0.124 | Standard Error 0.0313 | Liter | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population | QAW039 150 mg | 0.76 | 95% Confidence Interval 0.62 to 0.92 | Events/year | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population | QAW039 450 mg | 0.70 | 95% Confidence Interval 0.57 to 0.87 | Events/year | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population | Placebo | 0.93 | 95% Confidence Interval 0.76 to 1.12 | Events/year | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population | QAW039 150 mg | 0.62 | Standard Error 0.050 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population | QAW039 450 mg | 0.67 | Standard Error 0.050 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population | Placebo | 0.55 | Standard Error 0.051 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5 (ACQ-5) Score in Overall Population | QAW039 150 mg | -0.83 | Standard Error 0.055 | units on a scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5 (ACQ-5) Score in Overall Population | QAW039 450 mg | -0.77 | Standard Error 0.055 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02563067/results